Core Viewpoint - Lepu Medical (300003.SZ) has signed an agreement with Denmark's Sidera for the global development and commercialization rights of MWN105 injection, a triple agonist for GLP-1/GIP/FGF21, excluding Greater China [1] Group 1 - Shanghai Minwei Bio will receive a 9.99% equity stake in Sidera as part of the agreement [1] - The company is entitled to receive milestone payments totaling up to $1.01 billion [1] - Shanghai Minwei Bio will also earn sales commissions from Sidera [1] Group 2 - This agreement is expected to enhance the global positioning of the company's GLP-1 multi-target drugs and improve international competitiveness [1] - There are uncertainties associated with drug development and market launch, as well as the milestone payment amounts [1]